Lutropin alfa + Follitropin alfa
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Poor Response to Ovulation Induction
Conditions
Poor Response to Ovulation Induction
Trial Timeline
May 1, 2023 → Aug 1, 2024
NCT ID
NCT05405686About Lutropin alfa + Follitropin alfa
Lutropin alfa + Follitropin alfa is a approved stage product being developed by Merck for Poor Response to Ovulation Induction. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05405686. Target conditions include Poor Response to Ovulation Induction.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05405686 | Approved | Withdrawn |
Competing Products
7 competing products in Poor Response to Ovulation Induction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 33 |
| Cultured Thymus Tissue + Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus | Sumitomo Pharma | Approved | 85 |
| Lunesta | Sumitomo Pharma | Approved | 85 |
| Rosuvastatin Calcium | AstraZeneca | Phase 1 | 33 |
| Eltrombopag | Novartis | Phase 2 | 52 |
| Everolimus (Afinitor®) | Novartis | Phase 2 | 52 |
| Cabozantinib S-malate | Exelixis | Phase 2 | 49 |